Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study
Identifying factors that may impact vildagliptin’s efficacy could contribute to individualized treatment for patients with type 2 diabetes. In the current study, we aimed to assess the correlation between patient baseline triglyceride (TG) and efficacy of vildagliptin in Chinese patients with type 2...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2019/9347132 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568087864410112 |
|---|---|
| author | Lingli Zhou Xiaoling Cai Yingying Luo Fang Zhang Linong Ji |
| author_facet | Lingli Zhou Xiaoling Cai Yingying Luo Fang Zhang Linong Ji |
| author_sort | Lingli Zhou |
| collection | DOAJ |
| description | Identifying factors that may impact vildagliptin’s efficacy could contribute to individualized treatment for patients with type 2 diabetes. In the current study, we aimed to assess the correlation between patient baseline triglyceride (TG) and efficacy of vildagliptin in Chinese patients with type 2 diabetes in a post hoc analysis of the VISION study. TG-based subgroup analysis was performed to evaluate baseline TG’s impact on the decrease of glycated hemoglobin (HbA1c) in patients receiving vildagliptin plus low-dose metformin (VLDM) vs. high-dose metformin (HDM). Additionally, multivariate linear regression was performed to assess the association between baseline TG and HbA1c reduction at weeks 12 and 24 for patients receiving VLDM vs. HDM. For patients receiving VLDM, baseline TG≤2.03 mmol/L was associated with significantly greater HbA1c reduction vs. TG>2.03 mmol/L at week 12, but not at week 24. Additionally, multivariate linear regression analysis revealed a significant independent association and an association short of statistical significance between patient baseline TG and the HbA1c-reducing efficacy of VLDM at weeks 12 (P<0.001) and 24 (P=0.082), respectively, while such association was absent for HDM. Collectively, baseline TG was an independent predictive factor for the efficacy of a dipeptidyl peptidase-IV in treating type 2 diabetes during its initial use. |
| format | Article |
| id | doaj-art-8bf8f41aae81456fa77ee084aa89ba5a |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-8bf8f41aae81456fa77ee084aa89ba5a2025-02-03T00:59:44ZengWileyJournal of Diabetes Research2314-67452314-67532019-01-01201910.1155/2019/93471329347132Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION StudyLingli Zhou0Xiaoling Cai1Yingying Luo2Fang Zhang3Linong Ji4Peking University People’s Hospital, 11 Xizhimen Street, Xicheng District, Beijing 100044, ChinaPeking University People’s Hospital, 11 Xizhimen Street, Xicheng District, Beijing 100044, ChinaPeking University People’s Hospital, 11 Xizhimen Street, Xicheng District, Beijing 100044, ChinaPeking University People’s Hospital, 11 Xizhimen Street, Xicheng District, Beijing 100044, ChinaPeking University People’s Hospital, 11 Xizhimen Street, Xicheng District, Beijing 100044, ChinaIdentifying factors that may impact vildagliptin’s efficacy could contribute to individualized treatment for patients with type 2 diabetes. In the current study, we aimed to assess the correlation between patient baseline triglyceride (TG) and efficacy of vildagliptin in Chinese patients with type 2 diabetes in a post hoc analysis of the VISION study. TG-based subgroup analysis was performed to evaluate baseline TG’s impact on the decrease of glycated hemoglobin (HbA1c) in patients receiving vildagliptin plus low-dose metformin (VLDM) vs. high-dose metformin (HDM). Additionally, multivariate linear regression was performed to assess the association between baseline TG and HbA1c reduction at weeks 12 and 24 for patients receiving VLDM vs. HDM. For patients receiving VLDM, baseline TG≤2.03 mmol/L was associated with significantly greater HbA1c reduction vs. TG>2.03 mmol/L at week 12, but not at week 24. Additionally, multivariate linear regression analysis revealed a significant independent association and an association short of statistical significance between patient baseline TG and the HbA1c-reducing efficacy of VLDM at weeks 12 (P<0.001) and 24 (P=0.082), respectively, while such association was absent for HDM. Collectively, baseline TG was an independent predictive factor for the efficacy of a dipeptidyl peptidase-IV in treating type 2 diabetes during its initial use.http://dx.doi.org/10.1155/2019/9347132 |
| spellingShingle | Lingli Zhou Xiaoling Cai Yingying Luo Fang Zhang Linong Ji Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study Journal of Diabetes Research |
| title | Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study |
| title_full | Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study |
| title_fullStr | Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study |
| title_full_unstemmed | Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study |
| title_short | Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study |
| title_sort | baseline triglyceride level affected the efficacy of vildagliptin in treating type 2 diabetes a post hoc analysis of the vision study |
| url | http://dx.doi.org/10.1155/2019/9347132 |
| work_keys_str_mv | AT linglizhou baselinetriglyceridelevelaffectedtheefficacyofvildagliptinintreatingtype2diabetesaposthocanalysisofthevisionstudy AT xiaolingcai baselinetriglyceridelevelaffectedtheefficacyofvildagliptinintreatingtype2diabetesaposthocanalysisofthevisionstudy AT yingyingluo baselinetriglyceridelevelaffectedtheefficacyofvildagliptinintreatingtype2diabetesaposthocanalysisofthevisionstudy AT fangzhang baselinetriglyceridelevelaffectedtheefficacyofvildagliptinintreatingtype2diabetesaposthocanalysisofthevisionstudy AT linongji baselinetriglyceridelevelaffectedtheefficacyofvildagliptinintreatingtype2diabetesaposthocanalysisofthevisionstudy |